{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:54:57Z","timestamp":1777632897566,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04881-1","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:22:56Z","timestamp":1777436576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing artesunate in acute myeloid leukemia: a pharmacokinetic rationale derived from antimalarial data"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0556-3678","authenticated-orcid":false,"given":"Woei Jye","family":"Ong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"4881_CR1","doi-asserted-by":"publisher","unstructured":"Mancuso RI, Foglio MA, Olalla Saad ST (2021) Artemisinin-type drugs for the treatment of hematological malignancies. Cancer Chemother Pharmacol. 87(1):1\u201322. https:\/\/doi.org\/10.1007\/s00280-020-04170-5. Epub 2020 Nov 3. PMID: 33141328","DOI":"10.1007\/s00280-020-04170-5"},{"issue":"3","key":"4881_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3892\/ijo.2020.4966","volume":"56","author":"RG Armando","year":"2020","unstructured":"Armando RG, Mengual G\u00f3mez DL, Gomez DE (2020) New drugs are not enough\u2011drug repositioning in oncology: an update. Int J Oncol 56(3):651\u2013684. https:\/\/doi.org\/10.3892\/ijo.2020.4966","journal-title":"Int J Oncol"},{"issue":"6","key":"4881_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bph.15986","volume":"180","author":"Y Liu","year":"2023","unstructured":"Liu Y, Li H, Luo Z, Yu Y, Yang J, Zhang M, Law BYK, Huang Z, Li W (2023) Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS\/Bim and TFRC\/Fe2\u2009+\u2009pathways. Br J Pharmacol 180(6):701\u2013720. https:\/\/doi.org\/10.1111\/bph.15986","journal-title":"Br J Pharmacol"},{"issue":"1","key":"4881_CR4","doi-asserted-by":"publisher","first-page":"2255802","DOI":"10.1080\/16078454.2023.2255802","volume":"28","author":"Q Su","year":"2023","unstructured":"Su Q, Huang P, Luo X, Zhang P, Li H, Chen Y (2023) Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK\/STAT3 signaling. Hematology 28(1):2255802 Epub 2023 Oct 10. PMID: 37815490","journal-title":"Hematology"},{"issue":"3","key":"4881_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00280-018-3533-8","volume":"81","author":"JF Deeken","year":"2018","unstructured":"Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ (2018) A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol 81(3):587\u2013596. https:\/\/doi.org\/10.1007\/s00280-018-3533-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"4881_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L (2011) Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 10:263. https:\/\/doi.org\/10.1186\/1475-2875-10-263","journal-title":"Malar J"},{"key":"4881_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.fob.2012.05.002","volume":"2","author":"Z Wang","year":"2012","unstructured":"Wang Z, Hu W, Zhang JL, Wu XH, Zhou HJ (2012) Dihydroartemisinin induces autophagy and inhibits the growth of iron-loaded human myeloid leukemia K562 cells via ROS toxicity. FEBS Open Bio 2:103\u2013112 PMID: 23650588; PMCID: PMC3642128","journal-title":"FEBS Open Bio"},{"issue":"1","key":"4881_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01371-8","volume":"9","author":"E Grignano","year":"2023","unstructured":"Grignano E, Cantero-Aguilar L, Tuerdi Z, Chabane T, Vazquez R, Johnson N, Zerbit J, Decroocq J, Birsen R, Fontenay M, Kosmider O, Chapuis N, Bouscary D (2023) Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein. Cell Death Discov 9(1):97. https:\/\/doi.org\/10.1038\/s41420-023-01371-8","journal-title":"Cell Death Discov"},{"issue":"4","key":"4881_CR9","first-page":"552","volume":"84","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin C-S, Fleckenstein L (2011) Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous administration. Am J Trop Med Hyg 84(4):552\u2013559","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"4881_CR10","first-page":"373","volume":"47","author":"PN Newton","year":"2008","unstructured":"Newton PN, ter Kuile F, White NJ, Boele van Hensbroek M, Teja-Isavadharm P (2008) Simplified artesunate dosing guidelines for severe malaria: Pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 47(5):373\u2013394","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4881_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12936-022-04278-4","volume":"21","author":"F Gashe","year":"2022","unstructured":"Gashe F, Wynendaele E, De Spiegeleer B et al (2022) Degradation kinetics of artesunate for the development of an ex-tempore intravenous injection. Malar J 21:256. https:\/\/doi.org\/10.1186\/s12936-022-04278-4","journal-title":"Malar J"},{"key":"4881_CR12","unstructured":"Food and Drug Administration US (2020) Artesunate for injection (110\u00a0mg single\u2013dose vial) [Prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213036s000lbl.pdf"},{"issue":"6","key":"4881_CR13","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.21037\/tcr.2018.11.36","volume":"7","author":"C-Y Dou","year":"2018","unstructured":"Dou C-Y, Liu L-L, Li F, Liu L, Wang C-L, Wang L-N, Wang H-H, Zhang H, Chen M-T (2018) Cytotoxic effect of artesunate on myeloid leukemia cell lines through up-regulating miR-29c expression. Transl Cancer Res 7(6):1748\u20131750. https:\/\/doi.org\/10.21037\/tcr.2018.11.36","journal-title":"Transl Cancer Res"},{"issue":"1","key":"4881_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13020-024-00928-8","volume":"19","author":"J Chen","year":"2024","unstructured":"Chen J, Ding Z (2024) Natural products as potential drug treatments for acute promyelocytic leukemia. Chin Med 19:57. https:\/\/doi.org\/10.1186\/s13020-024-00928-8","journal-title":"Chin Med"},{"issue":"4","key":"4881_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04810-z","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, Wang Y, Yin C, Gong P, Zhang Z, Zhao L, Waxman S, Jing Y (2022) Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa\/Bim\/Mcl-1\/p-Chk1 axis. Cell Death Dis 13(4):379. https:\/\/doi.org\/10.1038\/s41419-022-04810-z","journal-title":"Cell Death Dis"},{"issue":"6","key":"4881_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bph.15986","volume":"180","author":"Y Liu","year":"2023","unstructured":"Liu Y, Li H, Luo Z, Yu Y, Yang J, Zhang M, Law BYK, Huang Z, Li W (2023) Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS\/Bim and TFRC\/Fe2\u2009+\u2009pathways. Br J Pharmacol 180(6):701\u2013720. https:\/\/doi.org\/10.1111\/bph.15986","journal-title":"Br J Pharmacol"},{"issue":"12","key":"4881_CR17","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00432-012-1292-1","volume":"138","author":"J Lee","year":"2012","unstructured":"Lee J, Zhang G, Wu X, Xu F, Zhou J, Zhang X (2012) Growth inhibitory effect of dihydroartemisinin on Bcr\/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-\u03baB modulation. J Cancer Res Clin Oncol 138(12):2095\u2013102. https:\/\/doi.org\/10.1007\/s00432-012-1292-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"4881_CR18","doi-asserted-by":"crossref","unstructured":"Kim C, Hyun Lee J, Kim S, Sethi G, Seok Ahn K (2015) Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model. Oncotarget 6:4020\u20134035. Retrieved from https:\/\/www.oncotarget.com\/article\/3004\/","DOI":"10.18632\/oncotarget.3004"},{"key":"4881_CR19","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.2147\/DDDT.S248872","volume":"14","author":"P Gao","year":"2020","unstructured":"Gao P, Shen S, Li X, Liu D, Meng Y, Liu Y, Zhu Y, Zhang J, Luo P, Gu L (2020) Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis. Drug Des Devel Ther 14:2091\u20132100. https:\/\/doi.org\/10.2147\/DDDT.S248872","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"4881_CR20","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.18632\/oncotarget.23274","volume":"9","author":"X Li","year":"2017","unstructured":"Li X, Gao Y, Zhang Q, Hu N, Han D, Ning S, Ao Z (2017) Dihydroartemisinin-regulated mRNAs and lncRNAs in chronic myeloid leukemia. Oncotarget 9(2):2543\u20132552. https:\/\/doi.org\/10.18632\/oncotarget.23274","journal-title":"Oncotarget"},{"key":"4881_CR21","doi-asserted-by":"crossref","unstructured":"Zhao X, Zhong H, Wang R, Liu D, Waxman S, Zhao L, Jing Y (2015) Dihydroartemisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxa-mediated pathway requiring iron and endoperoxide moiety. Oncotarget 6:5582\u20135596. Retrieved from https:\/\/www.oncotarget.com\/article\/3336\/text\/","DOI":"10.18632\/oncotarget.3336"},{"key":"4881_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.freeradbiomed.2018.12.011","volume":"131","author":"J Du","year":"2019","unstructured":"Du J, Wang T, Li Y, Zhou Y, Wang X, Yu X, Ren X, An Y, Wu Y, Sun W, Fan W, Zhu Q, Wang Y, Tong X (2019) DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic Biol Med 131:356\u2013369. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.12.011","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"4881_CR23","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00280-016-3038-2","volume":"77","author":"CD Drenberg","year":"2016","unstructured":"Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD (2016) Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemother Pharmacol 77(6):1231\u201343. https:\/\/doi.org\/10.1007\/s00280-016-3038-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4881_CR24","first-page":"575","volume":"35","author":"K Na-Bangchang","year":"2004","unstructured":"Na-Bangchang K, Krudsood S, Silachamroon U, Molunto P, Tasanor O, Chalermrut K, Tangpukdee N, Matangkasombut O, Kano S, Looareesuwan S (2004) The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers. Southeast Asian J Trop Med Public Health 35(3):575\u2013582","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"8","key":"4881_CR25","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1128\/AAC.01717-08","volume":"53","author":"DV Nguyen","year":"2009","unstructured":"Nguyen DV, Nguyen QP, Nguyen ND, Le TT, Nguyen TD, Dinh DN, Nguyen TX, Bui D, Chavchich M, Edstein MD (2009) Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob Agents Chemother 53(8):3534\u20137. https:\/\/doi.org\/10.1128\/AAC.01717-08","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4881_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12080748","volume":"12","author":"S Alven","year":"2020","unstructured":"Alven S, Aderibigbe BA (2020) Nanoparticles formulations of artemisinin and derivatives as potential therapeutics for the treatment of cancer, leishmaniasis and malaria. Pharmaceutics 12(8):748. https:\/\/doi.org\/10.3390\/pharmaceutics12080748","journal-title":"Pharmaceutics"},{"issue":"6","key":"4881_CR27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1365-2125.1998.00723.x","volume":"45","author":"KT Batty","year":"1998","unstructured":"Batty KT, Le AT, Ilett KF, Nguyen TS, Powell SM, Vuong TT (1998) A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria. Br J Clin Pharmacol 45(6):597\u2013603","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4881_CR28","first-page":"587","volume":"23","author":"Q Li","year":"2010","unstructured":"Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Miller RS, Melendez V, Weina PJ (2010) Pharmacokinetic profiles of artesunate after single intravenous doses in healthy volunteers: A phase I study. Curr Opin Infect Dis 23(6):587\u2013596","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"4881_CR29","volume":"16","author":"NJ White","year":"2017","unstructured":"White NJ (2017) Artemisinin resistance\u2014the clock is ticking. Malar J 16(1):187","journal-title":"Malar J"},{"issue":"13","key":"4881_CR30","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1073\/pnas.1217452110","volume":"110","author":"N Klonis","year":"2013","unstructured":"Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA (2013) Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc National Acad Sci 110(13):5157\u20135162","journal-title":"Proc National Acad Sci"},{"issue":"11","key":"4881_CR31","first-page":"4911","volume":"57","author":"B Witkowski","year":"2013","unstructured":"Witkowski B, Leli\u00e8vre J, Barrag\u00e1n MJL, Laurent V, Su X-Z, Mercereau-Puijalon O (2013) Increased tolerance of malaria parasites to artemisinin in vitro is linked to an altered temporal response to drug exposure. Antimicrob Agents Chemother 57(11):4911\u20134919","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4881_CR32","first-page":"51","volume":"30","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, White NJ (2014) The duration of chemoprophylaxis against malaria for travelers. Trends Parasitol 30(2):51\u201359","journal-title":"Trends Parasitol"},{"issue":"4","key":"4881_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ajps.2022.04.005","volume":"17","author":"KH Wong","year":"2022","unstructured":"Wong KH, Yang D, Chen S, He C, Chen M (2022) Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: a review. Asian J Pharm Sci 17(4):475\u2013490. https:\/\/doi.org\/10.1016\/j.ajps.2022.04.005","journal-title":"Asian J Pharm Sci"},{"key":"4881_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.leukres.2017.05.007","volume":"59","author":"B Kumar","year":"2017","unstructured":"Kumar B, Kalvala A, Chu S, Rosen S, Forman SJ, Marcucci G, Chen CC, Pullarkat V (2017) Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. Leuk Res 59:124\u2013135. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.007","journal-title":"Leuk Res"},{"issue":"5","key":"4881_CR35","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/cid\/cis958","volume":"56","author":"D Das","year":"2013","unstructured":"Das D, Tripura R, Phyo AP, Lwin KM, Tarning J, Lee SJ, Hanpithakpong W, Stepniewska K, Menard D, Ringwald P, Silamut K, Imwong M, Chotivanich K, Yi P, Day NP, Lindegardh N, Socheat D, Nguon C, White NJ, Nosten F, Dondorp AM (2013) Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis 56(5):e48-58. https:\/\/doi.org\/10.1093\/cid\/cis958","journal-title":"Clin Infect Dis"},{"key":"4881_CR36","doi-asserted-by":"publisher","unstructured":"Sompob Saralamba JA, Simpson N, Choosri L, White W, Pan-Ngum AM, Dondorp, Nicholas J, White An artesunate pharmacometric model to explain therapeutic responses in falciparum malaria. J Antimicrob Chemother, 78, Issue 9, September 2023, Pages 2192\u20132202, https:\/\/doi.org\/10.1093\/jac\/dkad219","DOI":"10.1093\/jac\/dkad219"},{"key":"4881_CR37","unstructured":"World Health Organization (2023) Guidance on the use of artesunate for severe malaria.https:\/\/extranet.who.int\/prequal\/sites\/default\/files\/whopar_files\/MA152part4v1_1.pdf"},{"key":"4881_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-200","volume":"8","author":"K Stepniewska","year":"2009","unstructured":"Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, Gansan\u00e9 A, Simpson JA, Morgan CC, White NJ, Kiechel J-R (2009) Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J 8:200. https:\/\/doi.org\/10.1186\/1475-2875-8-200","journal-title":"Malar J"},{"key":"4881_CR39","doi-asserted-by":"crossref","unstructured":"Fox JM, Moynihan JR, Mott BT, Mazzone JR, Anders NM, Brown PA, Rudek MA, Liu JO, Arav-Boger R, Posner GH, Civin CI, Chen X (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7:7268\u20137279. Retrieved from https:\/\/www.oncotarget.com\/article\/6896\/text\/","DOI":"10.18632\/oncotarget.6896"},{"issue":"1","key":"4881_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1056\/NEJMra052630","volume":"355","author":"E Estey","year":"2006","unstructured":"Estey E, D\u00f6hner H (2006) Acute myeloid leukemia. N Engl J Med 355(1):53\u201365. https:\/\/doi.org\/10.1056\/NEJMra052630","journal-title":"N Engl J Med"},{"issue":"12","key":"4881_CR41","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00228-006-0203-2","volume":"62","author":"PN Newton","year":"2006","unstructured":"Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul W, Ruangveerayuth R, White NJ (2006) The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur J Clin Pharmacol 62(12):1003\u20139. https:\/\/doi.org\/10.1007\/s00228-006-0203-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"4881_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02242-7","volume":"16","author":"F Li","year":"2025","unstructured":"Li F, Chen Y, Zhuang H, Pei R, Lu Y, Chen D, Li S, Ye P, Lian J, Lu Y (2025) A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC\/BCL-XL\/MCL-1 triple targeting. Discover Oncol 16(1):496. https:\/\/doi.org\/10.1007\/s12672-025-02242-7","journal-title":"Discover Oncol"},{"issue":"1","key":"4881_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.2042-7158.1996.tb05870.x","volume":"48","author":"KT Batty","year":"1996","unstructured":"Batty KT, Ilett KF, Davis ME, Davis T (1996) Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. J Pharm Pharmacol 48(1):22\u201326. https:\/\/doi.org\/10.1111\/j.2042-7158.1996.tb05870.x","journal-title":"J Pharm Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04881-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04881-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04881-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:23:12Z","timestamp":1777436592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04881-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4881"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04881-1","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work did not involve human participants or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"This manuscript presents a theoretical pharmacokinetic modeling framework intended solely for scientific discussion and should not be used to inform or direct clinical management.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"43"}}